Stiripentol in Dravet Syndrome

N/ANo Longer AvailableNCT01533506

Mayo Clinic

Overview

The patient has failed all other available agents and has intractable epilepsy due to Dravet Syndrome. Stiripentol is highly efficacious in Dravet Syndrome. The overall goals of therapy with Stiripentol are primarily to significantly reduce the frequency and severity of seizures.

Study Type

EXPANDED_ACCESS

Conditions

Dravet Syndrome

Interventions

stiripentolDRUG

Stiripentol up to 30 mg/kg/day to control seizures

Eligibility

Sex: FEMALEMin age: 11 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Genetic diagnosis of Dravet syndrome with intractable seizures despite failing all available medications for seizures

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.